Acne on AndroGel (testosterone topical): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence (trial data): ~10% in the key AndroGel 1% phase III trial; up to 8-10% across pooled TRT topical studies
• Typical onset: 4 to 12 weeks after starting therapy
• Body distribution: Upper back, shoulders, chest most common; face less frequent than in adolescent acne
• Severity: Predominantly mild to moderate (Grade 1-2); severe nodulocystic acne is rare (<1%)
• First-line management: Topical benzoyl peroxide or retinoids; dose review if DHT-driven worsening
• When to escalate: Persistent Grade 3 acne after 8 weeks of topical treatment, or any nodular/cystic lesions
• When to discontinue AndroGel: Severe nodulocystic acne unresponsive to dermatologic treatment; discuss risk-benefit with prescriber

What the Trial Data Actually Show

The most cited incidence figure for acne on AndroGel comes from the key phase III randomized trial published in the Journal of Clinical Endocrinology and Metabolism, which enrolled 227 hypogonadal men across AndroGel 50 mg, 100 mg, and placebo groups. Acne was reported in approximately 10% of participants in the active treatment arms, compared with lower rates in the placebo group. That 10% figure has been reproduced closely in subsequent open-label extensions and postmarketing surveillance data summarized in the FDA-approved AndroGel prescribing information, which lists acne as an adverse reaction occurring in ≥2% of patients.

The gap between the 2% threshold used for labeling and the ~10% trial figure is worth understanding. The label threshold captures reactions above a statistical floor across all reporting periods, whereas the 3-month active trial window captured early-onset events more densely. Both numbers are real. Patients should expect a roughly 1-in-10 probability during the first few months, not a 1-in-50 probability.

A 2010 systematic review of testosterone replacement in men and related meta-analyses confirm that acne and oily skin are consistently among the top three dermatologic complaints across all TRT delivery routes, though transdermal formulations generally produce steadier serum androgen levels than injections. That pharmacokinetic stability is thought to reduce the peak-driven sebaceous flares seen with intramuscular depot testosterone, which may explain why severe acne appears less common with gels than with weekly or biweekly injections.

Why Testosterone Causes Acne: The Androgen-Sebaceous Gland Axis

Sebaceous glands express androgen receptors throughout their secretory cells. When circulating testosterone rises, glandular cells respond by increasing sebum production, a lipid-rich secretion that normally lubricates the skin. At elevated or newly elevated androgen levels, excess sebum pools inside hair follicles, creating a substrate for Cutibacterium acnes (formerly Propionibacterium acnes) colonization.

The more biologically active driver is dihydrotestosterone (DHT), formed when 5-alpha reductase converts testosterone in peripheral tissues including the skin. Sebaceous gland cells are particularly rich in 5-alpha reductase type 1, making them highly sensitive to local DHT exposure. This is why men who develop significant acne on AndroGel sometimes benefit from dose reduction even when total testosterone remains within the reference range: DHT levels in skin tissue can exceed systemic measurements when conversion is brisk.

It is also why topical application site matters clinically. Men who apply AndroGel to the upper arms and shoulders, the most common application sites, may have direct local sebaceous stimulation at the skin overlying the application zone, producing regionally concentrated acne that differs in pattern from the systemic hormonal acne seen with injections.

Severity Distribution: What "Acne" Looks Like in Practice

Clinical grading of androgen-induced acne in TRT trials is inconsistently reported, but available data and dermatologic literature on adult-onset hormonal acne generally describe the following distribution:

Grade 1 (comedonal acne): Open and closed comedones, minimal inflammation. This is the most common presentation in AndroGel users and often goes unreported or self-managed. Patients describe small skin-colored bumps or blackheads on the upper back.

Grade 2 (mild-to-moderate papulopustular acne): Scattered inflamed papules and pustules, typically <20 lesions. Most trial-reported acne falls in this range. Responds well to topical benzoyl peroxide 2.5-5% or topical retinoids.

Grade 3 (moderate-to-severe papulopustular acne): More than 20 inflamed lesions, potential for scarring. Requires prescription topical therapy and possibly oral antibiotics. Dermatology referral is appropriate at this stage.

Grade 4 (nodulocystic acne): Painful cysts, high scarring risk. Rare on AndroGel alone (<1% in trial data). When it occurs, it warrants prompt dermatology evaluation and a serious conversation about whether AndroGel can continue at any dose.

The American Academy of Dermatology acne severity guidelines provide the standard grading framework used in dermatology practice and are a useful reference for both patients and non-dermatologist prescribers trying to calibrate when to refer.

Who Is Most at Risk

Not every AndroGel user develops acne, and pre-existing risk factors substantially increase the probability of a clinically significant flare:

Personal history of acne. Men who had moderate-to-severe acne during adolescence are more likely to see recurrence or worsening when exogenous androgen is added. Sebaceous gland sensitivity may persist even decades after adolescent acne resolves.

Younger age at TRT initiation. Hypogonadism in men under 40 is increasingly treated; younger skin tends to have higher baseline sebaceous activity.

Higher starting or maintenance doses. Men titrated to 100 mg/day AndroGel show modestly higher acne rates than those maintained at 50 mg/day in trial data, consistent with a dose-response relationship.

Elevated DHT at follow-up labs. DHT tends to rise proportionally more than testosterone in some men on topical TRT due to high local 5-alpha reductase activity in scrotal and truncal skin, even when total testosterone stays within range.

Family history of severe acne. Genetic variation in androgen receptor sensitivity and sebaceous enzyme expression is a real contributor. If a father or brother had severe cystic acne on much lower endogenous testosterone levels, the patient may carry similar receptor sensitivity.

Oily skin phenotype at baseline. Men who already report oily skin before starting AndroGel are effectively disclosing pre-existing sebaceous hyperactivity.

Timeline: When Acne Starts and Whether It Resolves

Onset typically follows the initial rise in serum testosterone, appearing 4 to 12 weeks into therapy as sebaceous glands respond to the new androgen signal. In the AndroGel phase III trial, most adverse events were captured within the first 90-day efficacy window, and acne was no exception.

The critical clinical point is that acne on AndroGel is not necessarily permanent. As the body equilibrates to a stable testosterone level, the sebaceous stimulus becomes constant rather than escalating. Many patients report noticeable improvement after months 3 through 6. This mirrors what is seen in other hormonal acne scenarios, such as acne improvement after oral contraceptive initiation in women, where the skin adjusts to a new hormonal steady state over one to two full follicular cycles.

However, improvement is not guaranteed. Men with genetic sebaceous sensitivity or those maintained at the higher end of the testosterone range may have persistent Grade 1-2 acne requiring ongoing management. The practical message: give the skin 3 to 6 months before concluding that acne will be a permanent fixture on therapy.

First-Line Management While Staying on AndroGel

For Grade 1-2 acne, the following approach is reasonable before involving dermatology:

1. Topical benzoyl peroxide (2.5-5%) applied to affected areas once or twice daily. BP is bactericidal against C. acnes and reduces follicular keratin plugging. It is available without a prescription.

2. Topical retinoids (tretinoin 0.025-0.05% or adapalene 0.1%) to normalize follicular keratinization. Adapalene 0.1% gel is now OTC in the United States.

3. Review AndroGel application sites. Shifting from shoulder application to a site with less dense sebaceous follicles (inner upper arm) may reduce localized flares.

4. Check serum DHT at the next follow-up lab draw. If DHT is above the upper limit of normal, a dose reduction conversation with the prescriber is warranted.

5. Non-comedogenic moisturizer and gentle cleanser. Overly aggressive washing triggers rebound sebum production and worsens comedonal acne.

For Grade 3 acne or any lesions that are nodular, a dermatology referral is appropriate. Oral doxycycline 100 mg daily for 8 to 12 weeks is a standard short-course option for inflammatory TRT-associated acne, per AAD guideline recommendations for moderate acne. Isotretinoin is effective for Grade 4 disease but requires careful coordination with the TRT prescriber.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://academic.oup.com/jcem/article/85/8/2839/2851105
• AndroGel (testosterone gel) 1% Prescribing Information. AbbVie Inc. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021015s039lbl.pdf
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes. J Clin Endocrinol Metab. 2010;95(6):2536-2559. https://academic.oup.com/jcem/article/95/6/2536/2833274
• Zouboulis CC, Degitz K. Androgen action on human skin. Br J Dermatol. 2004;150(suppl 66):7-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761243/
• Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne. J Am Acad Dermatol. 2009;60(5 suppl):S1-S50. https://www.aad.org/member/clinical-quality/guidelines/acne
• Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3 suppl):S200-S210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923944/